Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The company’s resorted platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer, and immunological disorders.
C2i Genomics, Inc. specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-surgery cancer patients. The company offers an ultra-sensitive liquid biopsy assay that analyzes subtle changes in tumor DNA, enabling physicians to monitor treatment responses and detect disease recurrence or treatment failure significantly earlier than traditional methods. C2i Genomics employs a bio-platform approach applicable across various cancer types, facilitating the guidance of multiple treatment modalities, including surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, the company provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. Established in 2019, C2i Genomics is headquartered in New York, New York, with a research and development center located in Haifa, Israel.
TerMir is an innovative AgTech company that offers pioneering solutions to address key, unresolved agronomic and environmental challenges.
At Cradle Genomics, their mission is to provide knowledge that helps every pregnancy. They're dedicated to the transformation of non-invasive prenatal testing (NIPT) by offering the most comprehensive fetal genetic analysis and pregnancy health screening solutions at the earliest stages of pregnancy.
Cradle Genomics is newly formed with their headquarters based in San Diego and additional R&D operations located in Detroit. Cradle tests are based on the genetic analysis of fetal cells that are quickly collected during a first trimester visit with no risk to the mother or developing fetus.
Strand Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2017. The company focuses on genetically programming mRNA to develop innovative therapies that enhance patient outcomes. Utilizing its mRNA programming technology, Strand Therapeutics creates gene therapies powered by synthetic biology, which include immunotherapies designed to stimulate cells to produce cancer-targeting proteins. This approach improves the immune system's ability to combat cancer by enabling precise control over the timing, location, and intensity of therapeutic protein expression. The technology leverages cell-type specific expression and responds to specific molecular signals, allowing for tailored therapeutic interventions.
Kinestral Technologies, Inc. specializes in manufacturing smart-tinting glass, branded as Halio, for both commercial and residential applications. Halio glass can transition from clear to tinted or dark, either automatically or on command, enhancing architectural design by providing versatile solutions for windows, walls, and skylights. This technology offers significant advantages over traditional electrochromic glass, including faster tinting, uniform coloration, and a natural appearance. Kinestral also provides a range of supporting products, such as the Halio Tint Selector, which allows localized control of window tinting, and Halio Cloud, an interface for integrating window operations with building automation systems. Founded in 2010 and headquartered in Hayward, California, Kinestral has established a strategic partnership with Asahi Glass Co., Ltd. Its advanced manufacturing techniques ensure reliable production and timely delivery for projects worldwide, ultimately aiming to improve energy efficiency and comfort in indoor environments.
Avidity Biosciences is a biopharmaceutical company specializing in the development of oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disorder. The company's development pipeline also includes programs focused on treating various muscle diseases, such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Additionally, Avidity is exploring therapeutic applications for immune and other cell types, leveraging its proprietary AOC platform to reach previously undruggable tissues and effectively target the genetic underpinnings of these conditions. Founded in 2012, Avidity Biosciences is headquartered in La Jolla, California.
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
Aitia is a big data analytics company that specializes in providing solutions for the healthcare industry. The firm utilizes advanced analytics to uncover effective treatments and identify the right patient populations. Aitia's Reverse Engineering and Forward Simulation Technology enables the automated extraction of causal network models from observational data, facilitating high-throughput simulations to generate new insights. The company offers real-world outcomes solutions derived from various data sources, including electronic health records and claims data, and supports product development for biopharmaceutical firms, diagnostic companies, and medical device manufacturers. Aitia serves a diverse clientele, including pharmaceutical and biotechnology companies, health plans, hospitals, and accountable care organizations. Founded in 2000 and based in Cambridge, Massachusetts, Aitia operates as a subsidiary of Via Science, Inc.
Arbor Biotechnologies operator of a bio-discovery company intended to provide human diagnostic development service. The company's platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, enabling drug developers to accelerate the discovery of proteins for improving human health and sustainability.
Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.
GenePeeks, Inc. is a genetic information company focused on helping families mitigate the risk of heritable diseases. Established in 2009 and based in New York, the company has developed a proprietary software platform that utilizes Next-Generation sequencing data to simulate the genetic recombination that occurs during human reproduction. By digitally weaving together the DNA of prospective parents, GenePeeks' technology generates analytic targets that represent tens of thousands of "virtual genomes," offering insights into the potential genetic profile of future children. This approach enables the identification of disease risks that are not detectable through existing pre-conception screening methods, providing valuable genetic insight for healthcare professionals and prospective parents.
AgriMetis LLC specializes in the research, development, and production of agricultural crop protection products. Founded in 2014 and headquartered in Lutherville, Maryland, with additional facilities in Research Triangle Park, North Carolina, and Gaithersburg, Maryland, the company focuses on creating sustainable solutions derived from natural products. AgriMetis offers a range of products, including fungicides, herbicides, insecticides, and nematicides, aimed at protecting crops from weeds, fungal diseases, and insect pests. The company emphasizes innovative and efficient production processes, providing farmers with safe and cost-effective options for crop protection.
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.
OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.
IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.
Aitia is a big data analytics company that specializes in providing solutions for the healthcare industry. The firm utilizes advanced analytics to uncover effective treatments and identify the right patient populations. Aitia's Reverse Engineering and Forward Simulation Technology enables the automated extraction of causal network models from observational data, facilitating high-throughput simulations to generate new insights. The company offers real-world outcomes solutions derived from various data sources, including electronic health records and claims data, and supports product development for biopharmaceutical firms, diagnostic companies, and medical device manufacturers. Aitia serves a diverse clientele, including pharmaceutical and biotechnology companies, health plans, hospitals, and accountable care organizations. Founded in 2000 and based in Cambridge, Massachusetts, Aitia operates as a subsidiary of Via Science, Inc.
Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.
Cydan Development, Inc. is a company focused on the development and commercialization of therapies for orphan and rare diseases, with a particular emphasis on rare genetic disorders. Founded in 2012 and located in Lincoln, Massachusetts, Cydan functions as an orphan drug accelerator, identifying and de-risking compounds with therapeutic potential. The organization conducts comprehensive studies to support the further development of treatments by biotechnology firms. Cydan has worked on therapies for conditions such as Niemann-Pick Disease Type C and IMR-687 for sickle cell disease. The company leverages strong relationships with academic institutions and patient advocacy groups, along with deep expertise in drug development, to foster successful product commercialization and advance treatment options for underserved patient populations.
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.
Oncofactor is a Seattle, Washington-based developer of cancer therapeutics that disrupt signaling pathways between tumors and the immune system.
Acylin Therapeutics
Series A in 2011
Acylin Therapeutics is the first company focused on developing inhibitors of cellular acetylation, an enzymatic mechanism fundamental to the molecular pathology of cancer, metabolic disease, and neurodegeneration. Recent discoveries by Acylin founders and other investigators have revealed protein acetylation as a cellular signal transduction regulator potentially as ubiquitous and important as phosphorylation by kinase enzymes. The Company has developed a platform technology to design specific acyltransferase inhibitors based on crystal structures, novel medicinal chemical approaches, and mechanistic understanding. Acylin has prioritized the p300 and CBP histone acetyl transferases [HATs] for initial drug discovery.
Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.
Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint of biological system to reveal novel discoveries and realize the promise of precision medicine.
The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions.
Metabolon was founded in 2000 and headquartered in Durham, North Carolina.
Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.
BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on developing innovative therapeutics utilizing nanotechnology, particularly in the fields of oncology, cardiovascular, autoimmune, and inflammatory diseases. The company specializes in nanoparticle-drug conjugates, which are designed to specifically target tumors, reduce toxicity, and facilitate drug combinations. Among its product offerings is Ovaprene, a non-hormonal contraceptive that provides extended protection. Cerulean Pharma has assembled a distinguished team, including a management team, board of directors, and scientific advisory board, all of whom possess extensive experience in business development and scientific research from prominent organizations and institutions.
Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.
Accelerator Corporation, established in 2003 and headquartered in Seattle, Washington, is a venture capital firm dedicated to early-stage investments in biotechnology companies. The firm focuses on incubation and emerging growth opportunities, investing up to $2 million in each selected company. Accelerator Corporation does not engage in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm boasts a proprietary network for deal flow and collaborates with notable partners such as Amgen Ventures and ARCH Venture Partners to provide essential resources, including investment capital and scientific expertise. In recent years, Accelerator has invested in nine companies, three of which have successfully raised over $114 million in follow-on financing. The firm has facilitated more than $143.5 million in total funding for its portfolio companies, reflecting its effective model for identifying and developing innovative biotechnologies. Through its extensive network, Accelerator Corporation continues to seek compelling investment opportunities that contribute to advancements in medicine and healthcare.
BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.
Magen BioSciences is a Biotechnology company located in 100 Beaver Street, Suite 101, Waltham, MA, United States.
Map Pharmaceuticals, Inc. is a development-stage company based in Mountain View, California, specializing in the creation of novel inhalation therapies for respiratory and systemic diseases. Founded in 2003, the company is advancing several proprietary product candidates through clinical development. These include Unit Dose Budesonide, aimed at treating pediatric asthma in children aged six months to eight years, and MAP0004, designed for migraine relief. Additionally, Map Pharmaceuticals is developing MAP0005 for adolescent and adult asthma and chronic obstructive pulmonary disease, as well as MAP0001, which targets Type 1 and Type 2 diabetes through pulmonary delivery via its Tempo inhaler. The company's focus is on delivering innovative treatments to improve patient outcomes across various health conditions.
Hypnion is a neuroscience drug discovery and development company that develops novel therapeutics for the treatment of central nervous system disorders. The company develops treatments for sleep- and wake-alertness disorders and circadian rhythm abnormalities. Hypnion offers SCORE-2004, a drug discovery platform that is able to measure drugs’ impact on sleep and wake parameters. Hypnion is acquired by Eli Lilly and Company. Hypnion was founded in 2000 and is based in Worcester, Massachusetts.
The mission of Integrated Diagnostics is to leverage powerful emerging technologies in the development of diagnostic products that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimer's through blood tests that can monitor tens to hundreds of disease markers simultaneously. The company plans to develop a pipeline of game-changing diagnostic products that enable the diagnosis and prognosis of a variety of diseases. The company is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules.
Accelerator Corporation, established in 2003 and headquartered in Seattle, Washington, is a venture capital firm dedicated to early-stage investments in biotechnology companies. The firm focuses on incubation and emerging growth opportunities, investing up to $2 million in each selected company. Accelerator Corporation does not engage in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm boasts a proprietary network for deal flow and collaborates with notable partners such as Amgen Ventures and ARCH Venture Partners to provide essential resources, including investment capital and scientific expertise. In recent years, Accelerator has invested in nine companies, three of which have successfully raised over $114 million in follow-on financing. The firm has facilitated more than $143.5 million in total funding for its portfolio companies, reflecting its effective model for identifying and developing innovative biotechnologies. Through its extensive network, Accelerator Corporation continues to seek compelling investment opportunities that contribute to advancements in medicine and healthcare.
Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint of biological system to reveal novel discoveries and realize the promise of precision medicine.
The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions.
Metabolon was founded in 2000 and headquartered in Durham, North Carolina.
Accelerator Corporation, established in 2003 and headquartered in Seattle, Washington, is a venture capital firm dedicated to early-stage investments in biotechnology companies. The firm focuses on incubation and emerging growth opportunities, investing up to $2 million in each selected company. Accelerator Corporation does not engage in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm boasts a proprietary network for deal flow and collaborates with notable partners such as Amgen Ventures and ARCH Venture Partners to provide essential resources, including investment capital and scientific expertise. In recent years, Accelerator has invested in nine companies, three of which have successfully raised over $114 million in follow-on financing. The firm has facilitated more than $143.5 million in total funding for its portfolio companies, reflecting its effective model for identifying and developing innovative biotechnologies. Through its extensive network, Accelerator Corporation continues to seek compelling investment opportunities that contribute to advancements in medicine and healthcare.
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.
MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, that specializes in the discovery and development of antibody-based therapeutics for cancer treatment. The company's pipeline includes several immuno-oncology candidates, such as Margetuximab, a monoclonal antibody currently in Phase III trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include various monoclonal antibodies targeting immune checkpoints like PD-1 and B7-H3, as well as combination therapies that leverage multiple targets. MacroGenics employs advanced Fc engineering technology to enhance antibody functionality and is also exploring applications for autoimmune disorders and infectious diseases. The company has established strategic collaborations with several partners to advance its research and development efforts. Founded in 2000, MacroGenics is committed to innovating immunotherapeutics to address significant medical needs.
Nanosys, Inc. specializes in developing and manufacturing quantum dot technology to enhance high-definition viewing experiences in the display industry. Founded in 2001 and based in Milpitas, California, the company offers a range of products, including Quantum Dot Concentrate material, quantum dot nanomaterials, and Quantum Dot Enhancement films. These products improve color performance and brightness in a variety of consumer electronics, such as tablets, televisions, smartphones, and automotive interiors. Nanosys' quantum dot technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs, and has been integrated into over 20 million devices across more than 400 unique products. The company also explores applications of its nanotechnology in areas beyond displays, such as agriculture.
Norak Biosciences, Inc., headquartered in Research Triangle Park, NC, is a private biotechnology company. Norak is utilizing its proprietary Transfluor technology to become a world leader in the discovery and development of drugs that regulate G protein-coupled receptors.
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.
GoAhead Software, Inc. specializes in developing integrated middleware solutions tailored for the telecom, military, and aerospace sectors. Founded in 1993 and based in Bellevue, Washington, the company provides products such as SelfReliant, a high availability and systems management tool, and the Application Ready Platform, which facilitates resource discovery, system model instantiation, and various management integrations. Additionally, GoAhead offers WebServer, an open-source web server designed for embedded device developers, supporting features like active server pages and user management. The company serves various development projects, including wireless base station controllers, defense applications, and industrial controllers, and has established a strategic alliance with SteelCloud, Inc.